



FOR IMMEDIATE RELEASE

TSX Venture Exchange: FYT

FYTOKEM ANNOUNCES ATRIUM BIOTECHNOLOGIES AS NEW MARKETING PARTNER

--Fast growing Aeterna subsidiary purchases personal care and nutraceutical distribution rights from Fytokem--

Saskatoon, Saskatchewan, Nov 29, 2002 - Fytokem Products Inc. (Fytokem), a leading producer of *Function-Certified™* plant-based ingredients, today announced that it has entered an agreement with Atrium Biotechnologies Inc. (Atrium) of Quebec City to market, on an exclusive, world-wide basis, two of Fytokem's leading products lines for the personal care and nutraceutical markets.

This long-term "Cooperation and License Agreement" with Atrium provides Fytokem with a significant upfront payment and firm minimum purchase commitments for purchases and pricing to the end of 2004. Sales commitments past this date are on a best efforts basis.

Fytokem and Dragoco Gerberding Inc. of Germany have agreed to dissolve their existing marketing contract.

"Atrium brings both marketing expertise and much-needed cash to the equation. Their firm commitments to purchase product allow us to plan our operations with greater certainty", says Art Hesje, President of Fytokem. "Atrium's impressive growth history, combined with their team of aggressive professionals will bring enthusiasm and results to the further development and marketing of our novel and efficacious products. This also allows the Company access the nutraceutical market with an established partner."

"The irreproachable quality of Fytokem's products as well as their credibility on the plant based bioactive market make them a perfect partner for our company", says Luc Dupont, CEO of Atrium. "We are proud of this new association which will allow Atrium to considerably enlarge the market share already covered by Fytokem and thus generate economic benefits for our two Canadian companies".

About Fytokem Products Inc.

Fytokem Products Inc. is a Canadian life sciences company engaged in the discovery and commercialization of novel *Function-Certified™* plant-based substances – extracts, phytochemicals and bioactive molecules – for use as ingredients in personal care, nutraceutical, pharmaceutical and bio-industrial products, both domestically and internationally. Fytokem has applied for several scientific patents, and has developed a proprietary commercial scale manufacturing process.

About Atrium Biotechnologies Inc.

Atrium develops and markets nutritional supplements as well as active ingredients and fine chemicals intended for the cosmetics, pharmaceutical, fine chemical and nutritional industries. With its multidisciplinary team and its vast international research and marketing network, Atrium acts as an exchange point for technology companies aiming for a rapid access to global markets or for those wishing to draw from Atrium's expertise to co-develop innovative ingredients that will meet the requirements of their main customers. With its subsidiaries, the Company markets over 500 products in 20 countries to industry leaders such as Estée Lauder, L'Oréal, Clarins, Chanel, Aventis, SanofiSynthelabo and Nestlé.

Atrium's 2001 sales were \$43.8 Million and reached \$73.2 Million after 9 months in 2002.

Atrium is a privately held subsidiary of the publicly traded pharmaceutical company Aeterna Laboratories Inc. (TSX:AEL; NASDAQ:AELA).

The Canadian Venture Exchange has neither approved nor disapproved the information herein contained.

-30-

For more information, please contact:

Art Hesje

President and CEO

Fytokem Products Inc.

306-668-2552 tel

306-978-2436 fax

ahesje@fytokem.com

www.fytokem.com